A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Table 3

Adverse events related to the second TACE procedure in the two groups before PSM analysis.

Adverse events	TACE + apatinib (n = 53)	TACE alone (n = 56)	value
Hepatorenal syndrome	1 (1.9%)	2 (3.6%)	1.000
Inguinal hematoma	2 (3.8%)	2 (3.6%)	1.000
Hepatic arterial dissection	1 (1.9%)	0 (0%)	0.228
Pulmonary oil embolization	0 (0%)	0 (0%)	———

TACE, transarterial chemoembolization; PSM, propensity score matching.